81 results about "Deamidation" patented technology

The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011 / 0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

The present invention relates to a method of enhancing the salty taste of a food or beverage containing salt which comprises adding an acidic peptide or a peptide obtained by subjecting a protein to hydrolysis and deamidation to the food or beverage, a salty taste enhancer comprising the peptide as an active ingredient, a salty taste seasoning agent comprising the peptide and salt, and a food or beverage comprising the salty taste enhancer or the salty taste seasoning agent.

A readily-soluble freeze-dried solid preparation of hGH with a minimal content of degradation products in terms of deamidation, dimers, polymers, and sulphoxide forms, obtainable by a method comprising a single lyophilization of an aqueous slurry of an amorphous hGH isoprecipitate, the slurry having a pH of from about 4.7 to 5.0 and being essentially free of buffer components other than acetate.

The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.

The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.

The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.

The present invention relates to antibodies with decreased deamidation profiles, and methods for producing antibodies with decreased deamidation profiles.

The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.

The present inventors revealed that deamidation of an antibody can be suppressed without influencing its activity by substituting a glycine that is located adjacent to an asparagine with another amino acid.

This invention relates to methods for controlling deamidation of at least one type of heterologously expressed polypeptide in cell culture.

The invention describes the patterns of deamidation in gluten, and it is found that this is highly dependent on the spacing between the glutamine and proline residues. This knowledge can be used to predict novel T cell stimulatory gluten peptides. Several newly defined peptides and epitopes are provided. Also, the finding can explain the formation of neo-epitopes in autoimmune diseases such as RA (rheumatoid arthritis), MS (multiple sclerosis), SLE (systemic lupus erythomatosus), SS (Sjogren syndrome) and DB (diabetes). Several neo-epitopes and the peptides that are substrate for deamidation are provided. Further, the inventions provides for methods for detecting these peptides and epitopes and methods for making food more suitable for celiac disease patients.

The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011 / 0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

A peptide which selectively inhibits αvβ3 integrin which comprises the deamidation product of a peptide comprising the NGR motif.

The invention discloses a method for preparing modified wheat gluten protein by decarboxamidation and organic acid. The method comprises the steps: the organic acid is dissolved in 5 to 15 percent (w / w) of wheat gluten protein suspension, the mass concentration of the organic acid in the wheat gluten protein suspension is 0.2 to 1.5 percent; the solution reacts at a temperature of 110 DEG C to 126 DEG C for 5 to 30 minutes and is cooled and diluted for 5 to 10 times before small molecular acid residue is removed by ultrafiltration, and the solution is condensed, sprayed and dried to obtain the modified wheat gluten protein. The method has simple production technology, low protein hydrolysis degree, high safety and strong feasibility of implementation, and the final product has high foamability and can be used for baking and swelling food.

The present inventors revealed that deamidation of an antibody can be suppressed without influencing its activity by substituting a glycine that is located adjacent to an asparagine with another amino acid.

The invention discloses a preparation method for an oxytocin deamidation impurity. The preparation method comprises the following step of: successively subjecting a solution of a crude oxytocin deamidation impurity precursor to reversed-phase cyclization, reversed-phase purification and reversed-phase desalination by adopting high-performance liquid-phase reversed-phase chromatography, wherein a filling material for the high-performance liquid-phase reversed-phase chromatography is silica gel C18; and the crude oxytocin deamidation impurity precursor contains two free sulfhydryl groups. The preparation method provided by the invention innovatively adopts a reversed-phase adsorption method for cyclization, purification and desalination, solves the problems of cyclization, purification and desalination once for all, optimizes the production process, and is applicable to continuous industrial production.

A method for improving the degree of deamidation (%) and the deamidation rate when deamidating a milk protein by an enzyme which exerts a deamidating effect by acting directly on an amide group of a protein without cleaving a peptide bond or crosslinking the protein is provided. A method for denaturing a milk protein enzymatically is also provided.A preliminarily denatured milk protein is deamidated by a protein deamidating enzyme which exerts a deamidating effect by acting directly on an amide group of a protein having a molecular weight of 5,000 or more without cleaving a peptide bond or crosslinking the protein. Such an enzyme can be used also for denaturing a milk protein.

The invention discloses gluten protein colloid granules and a preparation method and application of the gluten protein colloid granules. The preparation method comprises the following steps: gluten protein is subjected to crosslinking reaction under the effect of glutamine transaminase so as to form gluten protein colloid granules; micro hydrophilic molecules with primary amine groups are added into the reaction system, and are at least one of L-lysine, glucosamine and L-glutamic acid, and the mass ratio of micro hydrophilic molecules with primary amine groups to the gluten protein is 1 to (10-100). According to the invention, the micro hydrophilic molecules with primary amine groups are added into the reaction system; the gluten protein is subjected to crosslinking among molecules and within molecules, and crosslinking reaction is performed together with the micro hydrophilic molecules with primary amine groups; on one hand, glutamine or asparaginate in the gluten protein can be prevented from being subjected to deamidation reaction by glutamine transaminase, and on the other hand, because the micro hydrophilic molecules with the primary amine groups contains electrified groups, relatively high surface electric charge is given to the gluten protein.

The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.

The invention discloses a preparation method of wheat protolysate, belonging to the technical field of food processing. The preparation method comprises the following steps: by taking wheat protein as a raw material, mixing slurry, pretreating, neutralizing, adding complex enzyme for enzymatic hydrolysis reaction and deactivating enzyme and spray-drying to obtain a product wheat protolystate. Citric acid is adopted to pretreat wheat protein to have deamidation, the solubility of the wheat protein can be increased, the subsequent protease is favorably close to an enzyme digestion site, the enzyme utilization rate, solubility and enzymolysis speed can be increased. The wheat protolysate prepared by adopting the method is good in solubility, dispensing with obvious bitter taste, the content of small peptide is high, the protein is high digestion rate and easy to absorb, the bioavailability of the wheat protein can be greatly improved; and the preparation technology is simple, the time consumption is short, enzyme investment cost is low, and the preparation method is suitable for industrial production.

The invention relates to a preparation method and an application of a meat taste peptide. The method comprises the following steps: carry outing deamidation modification of wheat gluten proteins by an organic acid or an inorganic acid to the deamidation degree of 30-50%, carrying out enzymatic hydrolysis of the deamidated wheat gluten proteins by an acidic protease to the hydrolysis degree reaching 10-15%, centrifuging, filtering by an ultrafilter membrane, concentrating, and carrying out spray drying to obtain the meat taste peptide. The protein recovery rate of the method reaches above 90%, and the obtained meat taste peptide can be dissolved in 20% brine and has a typical meat taste, so the meat taste peptide can be widely applied in sausage products, instant soup stocks, meat cans and instant foods, and can improve the vegetable protein utilization rate and the food quality.

The embodiment of the invention discloses a cationic polymer, the main chain of the cationic polymer contains an amido bond or ester bond and triazole ring, and the lateral chain thereof contains alpha-amino group. The invention also provides a preparation method of the cationic polymer, comprising the following steps: performing click polymerization on aspartic acid or diyne monomer of glutamic acid under the protection of amino group and aspartic acid or bisazide monomer of glutamic acid under the protection of amino group under the existence condition of a catalyst to obtain the cationic polymer under the protection of amino group; and performing deamidation protection on the cationic polymer under the protection of amino group to obtain the cationic polymer. Compared with the biological fermentation method in the prior art, the preparation method provided by the invention is simple and efficient, and the prepared cationic polymer has higher molecular weight.

A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.

A method of treating a neurologic or neuropsychiatric disorder or disease in a mammal is provided. The method comprises administering a fatty acid amide hydrolase inhibitor in an amount sufficient to inhibit deamidation of a fatty acid amide. A method of identifying a fatty acid amide hydrolase inhibitor useful in the treatment of a neurologic or neuropsychiatric disorder is also provided. A method of identifying a fatty acid amide or fatty acid useful in the treatment of a neurologic or neuropsychiatric disorder is also provided.

The invention discloses a preparation method of (S, S)-octahydro-6H-pyrrolo[3, 4-b]pyridine. The method includes: taking dipicolinic acid as the raw material, which is subjected to dehydration, ammonolysis, cyclization, pyridine ring hydrogenation, imide reduction, chiral separation, amino amidation, deamination, hydrogenation debenzylation, and deamidation, thus obtaining a target product. Specifically, the pyridine ring hydrogenation reaction is finished in a short time under low temperature and low pressure conditions. The imide reduction reaction adopts a cheap reducing agent, and has the characteristics of mild conditions, high yield, low cost, safety and reliability. The hydrogen debenzylation reaction undergoes under normal atmospheric pressure and normal temperature, thus avoiding the formation of by-products and lowering energy consumption. The preparation method provided by the invention has the advantages of simple process, low cost, mild and easily controllable reaction conditions, as well as safe and reliable production process, thus being suitable for industrialized production.

Disclosed is a novel method for improving an enzyme capable of deamidating a protein. A mutant enzyme can be designed by the following steps (1) and (2): (1) specifying at least one amino acid residue among amino acid residues corresponding to the amino acid residues located at position-35, position-38, position-39, position-40, position-41, position-42, position-43, position-45, position-46, position-49, position-79, position-80, position-81, position-82, position-83, position-84, position-103, position-104, position-105, position-106, position-117, position-142, position-143, position-146, position-166 and position-185 in the amino acid sequence depicted in SEQ ID NO:2 which is an amino acid sequence for a protein deamidase (an enzyme to be mutated); and (2) constructing an amino acid sequence having the substitution of the amino acid residue specified in step (1) by another amino acid residue or having the deletion of the amino acid residue specified in step (1) by using the amino acid sequence for the enzyme to be mutated as a base sequence.

A recombinant adeno-associated virus (rAAV) vector comprising an AAVhu68 capsid produced in a production system comprising a nucleotide sequence of SEQ ID NO: 1, or a sequence at least 75% identical thereto which encodes SEQ ID NO:2. The AAVhu68 capsid comprises subpopulations of highly deamidated asparagine residues in asparagine glycine pairs in the amino acid sequence of SEQ ID NO: 2. Also provided are compositions containing the rAAV and uses thereof. Additionally, rAAV having an engineered AAV capsid comprising at least one subpopulation of vp1 or vp2 proteins having a Val at amino acid position 157 with reference to the AAVhu68 vp1 numbering are provided.

A fat-free or low-fat yoghurt having a rich and creamy texture like yoghurts produced using whole-fat milk may be produced by adding a proper amount of a milk protein, such as a defatted milk powder, that has been deamidated with a protein deamidating enzyme to a fat-free or low-fat raw material milk. Alternatively, a proper amount of a milk protein, such as a defatted milk powder, is added to a fat-free or low-fat raw material milk, and the resulting mixture is subjected to a deamidation treatment with a protein deamidating enzyme so that the deamidation ratio reaches a proper level. In this manner, a fat-free or low-fat milk raw material having a milk protein mass and a deamidation ratio both falling within proper ranges can be prepared, and yoghurt may be produced using the milk raw material.